Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hydra Biosciences
Merck Research Laboratories president Roger Perlmutter returned to the company when its R&D was at a crossroads. Now he is retiring and handing the company’s post-Keytruda growth over to SVP Dean Li.
Boehringer Ingelheim is seeking partners with early-stage, novel approaches to neuropsychiatry disorders under its strategy of applying "fresh thinking" to diseases of the central nervous system with high unmet need.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Research/Analytical, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April 2015.